<html><body>
<h2>Case: Test Case: DM Minor lesion 4 weeks ago</h2>
85.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Overall_ADL</td><td width="200">6.0</td><td width="200">2008-2-3</td></tr>
<tr><td width="200">Age</td><td width="200">85</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Average_Pain_in_Last_Week</td><td width="200">8.0</td><td width="200">2008-2-3</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-04</td>
<td width="200">Febijuana UDS</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-14</td>
<td width="200">minor lesion</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Cardiovascular disease, unspecified</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Angina</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Myocardial_Infarction</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Atrial_Tachycardia</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Heart_Failure</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Pacemaker</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Rheumatic_Disease_Complicated_by_Heart_Failure</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">PVD</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Coronary_Artery_Disease</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Cardiomyopathy</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-01-05</td>
<td width="200">Amphetamines UDS</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Minor lesion diagnosed ~4weeks ago</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Heart_Block_2nd_Or_3rd_Degree</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Cardiomegaly</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Hypertension_Complicated_by_Heart_Failure</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-12-22</td>
<td width="200">Hypertension</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(85.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
<li><b>Low risk with minor wound <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Minor wound/lesion YES</i> evaluate to <b> true</b> because <i>minor lesion(yes compared to yes)</i>)])
•	Provide local wound care: cleanse wound with saline, remove necrotic and callus tissue, apply appropriate dressing, and other indicated treatments.
•	Offload pressure and weight, as indicated: consider lesion site and then provide pressure relief (e.g., special shoes and insoles and bed rest). To avoid further trauma to the lesion site, use a post-operative shoe, offloading, or depressurization footwear based on the lesion site(s).
•	Follow-up on a specified schedule: VA facility specific patients with active lesions need to be followed at least monthly.
•	Review the Self-Management and Education Module (Module S): reinforce nutrition, exercise and diabetes self-management. Avoid initiation of a calorie restriction diet for weight loss in patients with foot lesions.
•	Provide patient and family education.
•	Refer for foot care assistance, as needed, for patients unable to carry-out local wound care. Educate a family member on local wound care or refer the patient to a home health service.

</ul>
<li><b>General Rec</b><br>
<ul>
<li><b>General recs <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Confirm follow-up by foot care specialist if indicated and compliance by patient.
All patients and their families should receive self-management education for preventive foot care and selection of footwear. Instruction should include recommendations for daily foot inspection and preventive foot care, skin care, and use of emollients, nail care, and treatment for callus. Document.
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No target  or no HbA1C
<p><b>Action Choices</b>
<ul>
<li><b>Lack target or lack HbA1C</b><br>
<ul>
<li><b>Determine goal <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence Target HBA1c</i> evaluate to <b> true</i>)])

<li><b>Order HbA1C <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No HbA1C ever or in past year</i> evaluate to <b> true</b> because <i>null</i>)])
null
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(85.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class II a</b>
<ul>
<li>Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)()
</ul>
<li><b>Class I</b>
<ul>
<li>Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)()
<li>Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)()
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).()
</ul>
<li><b>Class III</b>
<ul>
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage C HF</b><br>
<ul>
</ul>
<li><b> </b><br>
<ul>
<li><b>General Recommendations <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HF ICD9 code OR( signs and structural abnormality)</i> evaluate to <b> true</b> because <i>null</i>)])
Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)
Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)

Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)
<li><b>Referrals <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])
Class I
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>aldosterone antagonist
<ul>
<li>Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.
<li>preference: preferred
</ul>
<li>hydralazine and nitrates
<ul>
<li>Recommend starting with hydralazine 25mg tid and nitrates 10mg tid. Would not go much above hydralazine 50mg tid and nitrates 40mg tid. Titrate after a month. Beta blockers can avoid the tachycardia caused by hydralazine and nitrates.
<li>preference: preferred
</ul>
<li>Beta blocker for stage C heart failure
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Beta blocker Stage C with MI
<ul>
<li>preference: preferred
<li>No comment
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font>
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>digoxin
<ul>
<li>Initial recommended dose of digoxin is 0.125mcg daily (or every other day).
<li>parameterized message: dig dose if age>70, egfr<30 or lean body mass
<li>Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced LVEF to decrease hospitalizations for HF (Level of Evidence: B).  ADD ADDL INFO from HF experts to help guide choice of when to add dig
<li>preference: preferred
</ul>
<li>Beta blocker stage B post MI
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>Beta Blocker Stage B no MI
<ul>
<li>preference: preferred
<li>No comment
</ul>
<li>NDHP CCB
<ul>
<li>Contraindications:  Heart_Failure(Hypertension_Complicated_by_Heart_Failure, Cardiomyopathy, Cardiomegaly, Rheumatic_Disease_Complicated_by_Heart_Failure, Heart_Failure)  Myocardial_Infarction(Myocardial_Infarction) 
<li>preference: ruled out
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
</body></html>
